Abstract
Interferon alpha as well as Interleukin 2 were extensively used during the past decade specially in the treatment of metastatic renal cell carcinoma (MRCC). Interferon alpha (IFN) gave response rates from 5 to 15% and Interleukin 2 (IL2) was reported to give 8 to 35% response rate including 5 to 10% of complete persistent remissions. Our past experience using either IV IL2 alone or together with IFN or this combination subcutaneously gave response rates from 15 to 25% and these results do not seem different according to the treatment modalities. In 1991, together with our French colleagues, we designed a randomized trial in MCRR. Patients could receive continuous infusion of IL2, or IFN or combination of both cytokines. Different clinical prognosis factors as well as putative prognosis biologic parameters were taken into account response rates and survival are the major end-points of this study. 470 patients were registered in 4 years and inclusion will stop by 30 June 1995. The data we expected from this trial could give us bases to select patients who may benefit of this treatment. In addition, new approaches in the treatment of MCRR must be set up.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
